Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 0.53 |
| ▸ | PPARA | Q07869 | 4/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | PPARD | Q03181 | 1/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | ACSL1 | P33121 | 2/20 | 0.46 |
| ▸ | ACSL6 | Q9UKU0 | 2/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | ALB | P02768 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2046234 | 0.99 | PPARA (0.52) | DHFRPPARAFFAR1PPARGPPARD | |
| SCHEMBL29402124 | 0.96 | DHFR (0.48) | DHFRPPARAFFAR1PPARGPPARD | |
| SCHEMBL120379 | 0.96 | DHFR (0.48) | DHFRPPARAFFAR1PPARGPPARD | |
| SCHEMBL30215712 | 0.84 | CD274 (0.46) | DHFRFFAR1CNR1CNR2 | |
| SCHEMBL16301494 | 0.84 | PDE3B (0.43) | FFAR1CNR1CNR2 | |
| Aminodiphenylmethane SCHEMBL1963354 | 0.84 | NR1H3 (0.46) | DHFRFFAR1PTPN1 | |
| SCHEMBL8355715 | 0.84 | PPARA (0.56) | DHFRPPARAFFAR1PPARGPPARD | |
| SCHEMBL1008175 | 0.84 | PPARA (0.56) | DHFRPPARAFFAR1PPARGPPARD | |
| SCHEMBL17593842 | 0.83 | DHFR (0.50) | DHFRPPARAFFAR1PPARGPPARD | |
| SCHEMBL2016744 | 0.82 | CNR2 (0.46) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1992 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122011136-A | Mutant of pre-fusion human metapneumovirus F protein and application thereof | 北京民海生物科技有限公司 | 2026-05-12 | — | — | CN | claimed |
| WO-2026090596-A1 | SYSTEMS AND DEVICES FOR ADMINISTRATION OF RNA VACCINES AND METHODS OF USE THEREOF | PIEZO THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4133097-B1 | IMPROVED METHODS OF PRODUCING A LIPIDATED PROTEIN | VALNEVA AUSTRIA GMBH (AT) | 2026-04-29 | — | — | EP | claimed |
| EP-4731207-A2 | INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMOVIRUS | Merck Sharp & Dohme LLC (US) | 2026-04-29 | — | — | EP | claimed |
| EP-4719469-A1 | COMBINATION CONTAINING AN MRNA VACCINE OR AN MRNA ENCODED THERAPEUTIC PROTEIN AND AN IMMUNE MODULATING MRNA FOR IMPROVED OR REDUCED IMMUNOGENICITY TO INCREASE EFFICACY | Imgen-T-Srl (IT) | 2026-04-08 | — | — | EP | claimed |
| US-12565494-B2 | Inhibitors of human respiratory syncytial virus and metapneumovirus | MERCK SHARP & DOHME LLC | 2026-03-03 | — | — | US | claimed |
| US-20260041734-A1 | M-CSF FOR USE IN THE PROPHYLAXIS AND/OR TREATMENT OF VIRAL INFECTIONS IN STATES OF IMMUNOSUPPRESSION | UNIV DRESDEN TECH (DE) | 2026-02-12 | — | — | US | claimed |
| EP-4688751-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | Enanta Pharmaceuticals, Inc. (US) | 2026-02-11 | — | — | EP | claimed |
| EP-4665737-A1 | PHOSPHOLIPID COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. (US) | 2025-12-24 | — | — | EP | claimed |
| EP-3368562-B1 | ANTIBODY NEUTRALIZING HUMAN RESPIRATORY SYNCYTIAL VIRUS | MERCK SHARP & DOHME LLC (US) | 2025-12-17 | — | — | EP | claimed |
| WO-2022025984-A1 | UNIVERSAL ANTIGEN-SPECIFIC T CELL BANKS AND METHODS OF MAKING AND USING THE SAME THERAPEUTICALLY | BAYLOR COLLEGE OF MEDICINE (US) | 2022-02-03 | — | — | WO | claimed |
| CN-113969324-A | Visual detection kit | 佛山科学技术学院 | 2022-01-25 | — | — | CN | claimed |
| US-7881871-B2 | Method for designing surfaces | BIO-LAYER PTY LIMITED (AU) | 2011-02-01 | — | — | US | claimed |
| EP-1700244-A4 | A METHOD FOR DESIGNING SURFACES | BIO LAYER PTY LTD (AU) | 2009-07-08 | — | — | EP | claimed |
| US-20070099235-A1 | Method for designing surfaces | BIO-LAYER PTY LIMITED (AU) | 2007-05-03 | — | — | US | claimed |
| EP-1700244-A1 | A METHOD FOR DESIGNING SURFACES | Bio-Layer Pty Limited (AU) | 2006-09-13 | — | — | EP | claimed |
| WO-2005057462-A1 | A METHOD FOR DESIGNING SURFACES | BIO-LAYER PTY LIMITED (AU) | 2005-06-23 | — | — | WO | claimed |
| EP-1018526-B1 | Process for preparing polyurethane foam | GEN ELECTRIC (US) | 2004-10-20 | — | — | EP | claimed |
| US-6660781-B1 | Reaction product of tertiary amine and phenoxy acid generates a delayed action catalyst to delay the onset of a reaction between said polyisocyanate, water, and organic polyol | WITCO CORPORATION | 2003-12-09 | — | — | US | claimed |
| EP-1018526-A1 | Process for preparing polyurethane foam | CK WITCO CORPORATION (US) | 2000-07-12 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260041734-A1 | M-CSF FOR USE IN THE PROPHYLAXIS AND/OR TREATMENT OF VIRAL INFECTIONS IN STATES OF IMMUNOSUPPRESSION | CD14, CSF1R, CSF3R | DHFR 3423/4885PPARA 1846/4885FFAR1 603/4885 |
| US-12565494-B2 | Inhibitors of human respiratory syncytial virus and metapneumovirus | NHERF1, ZC3HAV1, SARS1 | DHFR 4133/4885PPARA 4436/4885FFAR1 4207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.